Kornimate/medical-research-clean huggingface dataset:
circulating non-coding rna in acute ischemic stroke with endovascular treatment (evtrna)

Conditions: Stroke, Acute; Stroke, Ischemic; Endovascular Treatment

Summary: evtrna is to analyze the differentiated expression pattern of circular rna (circrna), long non-coding rna (lncrna) and micro-rna (mirna) by next-generation sequencing in acute ischemic stroke patients before and/or after endovascular treatment. the candidate circrna/lncrna/mirna will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. further, the candidate non-coding rna will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke.

noncoding rnas have been highlighted to be involved in the pathological process of ischemic stroke (is). the purpose of this protocol will investigate the differentiated expression pattern of circular rna (circrna), long non-coding rna (lncrna) and micro-rna (mirna) by next-generation sequencing in acute ischemic stroke patients before and/or after endovascular treatment. the candidate circrna/lncrna/mirna will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. further, the candidate non-coding rna will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke. distinctive expression patterns of circrna/mirna/lncrna will be identified by the next-generation sequencing and individual quantitative real time polymerase chain reaction (qrt-pcr). a predictive model will be established using logistic regression. the panel of these altered ncrnas may be associated with the immune status after acute is and could serve as a regulator for progression and prognosis of acute ischemic stroke with endovascular treatment.

Eligibility criteria:
inclusion criteria: * aged 18 years or older * confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (mri) and a new lesion on a brain computed tomography (ct) scan * within 24 hours of symptom onset and treat with endovascular therapy * good performance status * signed an approved informed consents exclusion criteria: * a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases

Keywords: acute ischemic stroke noncoding rna endovascular treatment clinical significance outcome
impact of mk-0954a on uric acid in the management of hypertension (mk-0954a-366)

Conditions: Hypertension

Summary: this was a retrospective, chart review, observational study to assess the effect of mk-0954a (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg \[hyzaar(r)\]) treatment for a period of at least three months on serum uric acid levels.


Eligibility criteria:
inclusion criteria: * participant was \>20 years and \<75 years of age on the index date (i.e., the date of initiating mk-0954a therapy) * diagnosed with hypertension and had received mk-0954a 50/12.5 mg for at least 3 months * had at least one serum uric acid measurements at baseline and one at 3 months after using mk-0954a 50/12.5 mg * had the following records documented in the chart during the data collection period: * medical history and co-morbidities (if available) * sitting blood pressure, serum uric acid, lipid profile test results before and after using mk-0954a 50/12.5 mg * serum electrolytes, serum creatinine, and pre-meal sugar (if available) * prescription information of all antihypertensive regimens exclusion criteria: * had been treated with diuretic or angiotensin-receptor blockers (arbs) 2 weeks before initiated treatment with mk-0954a 50/12.5 mg * serum creatinine \>2 mg/dl

Keywords: essential hypertension uric acid retrospective hyzaar
gene therapy with hlb-001 in pediatric patients with severe methylmalonic acidemia

Conditions: Methylmalonic Acidemia

Summary: the sunrise trial is a first-in-human (fih), open-label, phase 1/2 clinical trial designed to assess the safety, tolerability and preliminary efficacy of a single intravenous infusion of hlb-001 in pediatric patients with mma characterized by methylmalonyl-coa mutase gene (mmut) mutations. hlb-001 is a liver-targeted, recombinant engineered adeno-associated viral (raav) vector utilizing the lk03 capsid (raav-lk03), designed to non-disruptively integrate the human methylmalonyl-coa mutase gene at the albumin locus. the trial is expected to enroll pediatric patients with ages ranging from 6 months to 12 years, initially starting with 3 to 12 year-old patients and then adding patients aged 6 months to 2 years.


Eligibility criteria:
inclusion criteria: * at the time of dosing, participants must be 6 months to 12 years of age * males and females with diagnosis of severe mma meeting all the following; 1. isolated mma with genetically confirmed, pathogenic mutations in the mmut gene 2. screening serum/plasma methylmalonic acid level of \>100 µmol/l 3. one or more of the following considered by the pi to be mma-related: (i) an unscheduled er visit, hospitalization or requirement for sick day diet in the year prior to screening visit (ii) developmental delay, movement disorder, optic neuropathy or feeding disorder with tube feeding requirement 4. medically stable for the 2 months prior to the start of screening exclusion criteria: * participants with organic acidemias other than isolated mma, or with any other causes of hyperammonemia * having received mma-targeted gene therapy or nucleic acid therapy * participants on insulin or high dose hydroxocobalamin (\> 1 mg/day ohb12 parenteral) * kidney or liver transplant, including hepatocyte cell therapy * estimated glomerular filtration rate (egfr) of \< 60 ml/min/1.73 m2 based on age appropriate equations, or ongoing dialysis for renal disease * participant tests positive for anti-raav-lk03-neutralizing antibodies

Keywords: inborn errors of metabolism mut0 mut- mut deficiency organic acidemia sunrise
continuous versus short infusions of ceftazidime in cystic fibrosis

Conditions: Cystic Fibrosis; Pseudomonas Aeruginosa; Pulmonary Exacerbation

Summary: the aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary pa infection. in conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.

each patient received two successive iv antibiotic courses during a period of pulmonary exacerbation. one of these courses was delivered as thrice daily 30-minute infusions of ceftazidime in 100 ml of 0.9% sodium chloride, and the other was delivered as a continuous infusion of ceftazidime in 230 ml of 0.9% sodium chloride, over 23 hours. the daily dose of ceftazidime was 200 mg/kg, with a maximum dose of 12 g. for ceftazidime continuous infusion, a loading dose of 60 mg/kg (maximum 2 g) was used. all patients also received tobramycin (10 mg/kg), in the form of one 30-minute infusion per day. portable devices were used: intermate® sv 200 (baxter) for the 30-minute short infusions of ceftazidime and tobramycin, infusor® lv10 (baxter) for continuous infusion of ceftazidime.

Eligibility criteria:
inclusion criteria: * patients with cystic fibrosis older than 8 years * with chronic pseudomonas aeruginosa infection of the respiratory tract * with at least 2 courses of iv antibiotic in the year before enrolment * at the time of a pulmonary exacerbation exclusion criteria: * allergy to ceftazidime or tobramycin * bronchial colonization with burkholderia cepacia * renal impairment * history of lung transplantation

Keywords: ceftazidime continuous infusion antibiotic course
pattern of growth and characteristics of down syndrome pediatrics patients

Conditions: Growth Disorders

Summary: down syndrome or down's syndrome (ds), also known as trisomy 21, is a genetic disorder caused by the presence of all or part of a third copy of chromosome 21. it is usually associated with physical growth delays, mild to moderate intellectual disability, and characteristic facial features. the parents of the affected individual are usually genetically normal. the probability increases from less than 0.1% in 20-year-old mothers to 3% in those of age 45 .

people with ds may have some or all of these physical characteristics: a small chin, slanted eyes, poor muscle tone, a flat nasal bridge, a single crease of the palm, and a protruding tongue due to a small mouth and relatively large tongue. other features include: a flat and wide face, a short neck, excessive joint flexibility, extra space between big toe and second toe, abnormal patterns on the fingertips and short fingers. short stature is a characteristic feature of ds. growth retardation of ds individuals starts prenatally. after birth, the growth velocity is most reduced between 6 months to 3 years . growth charts specific for children with ds are important tools for routine medical follow-up, as well as early identification of pathological causes of growth retardation, and monitoring of growth promoting treatments. growth charts for ds are available from different countries, for example, italy, usa, denmark, sweden, portugal, france, uk and ireland and saudi arabia .

Eligibility criteria:
inclusion criteria: * all down syndrome children attending assuit university less than four years with or without cardiovascular. exclusion criteria: * any down syndrome child more than four years.
a clinical trial to evaluate the vision correction safety and efficacy of msihy silicone hydrogel soft contact lens

Conditions: Myopia; Refractive Errors

Summary: this is a prospective, randomized, double-blind, parallel, active-controlled, multi-center clinical study. the purpose is to evaluate the safety and effectiveness wearing "msihy silicone hydrogel soft contact lens". subjects will be randomized in 1:1 ratio to wear either the investigational device "msihy silicone hydrogel soft contact lens" or the control device monthly silicone hydrogel contact lenses(oa)".


Eligibility criteria:
inclusion criteria: 1. must be 18 years of age inclusive 2. beside myopia and astigmatism, subjects with normal eyes and are not using any ocular medications (excluding ocular lubricants and artificial tears) 3. best spectacle corrected visual acuity greater than or equal to 1.0 for both eyes 4. with +8.00d \~ -12.00 d spherical component myopia, and ≤1.00 astigmatism (based on manifest refraction measurements) 5. have worn soft contact lens for at least 2 month prior to the study 6. willing to comply with the required wearing time 7. agree to comply with all study procedures, sign and date the informed consent form before starting the clinical study exclusion criteria: 1. anterior segment infection, inflammation or abnormality 2. any active ocular disease that would affect contact lens wear or vision (such as acute and subacute inflammation of the anterior chamber of the eye, eye infection, uveitis, serious palpebral abnormality, corneal hypoesthesia, corneal epithelium abrasion, dry eye and tear duct defection, ocular allergies, highly suspected glaucoma) upon evaluation by the investigators or slit lamp findings 3. currently using systemic or ocular medications that would contraindicate contact lens wear (such as glaucoma eye drops, steroid anti-inflammatory drops, eye ointments, eye gels and other eye medicines) 4. history of herpetic keratitis 5. history of refractive surgery, keratoconus or irregular cornea 6. slit lamp findings that are not suitable for inclusion (details of the grading standards for each eye condition are specified in cip section 5.7.5) 7. a pathologically dry eye (schirmer test 1 \<5 mm) 8. have participated in any contact lens or contact lens care product clinical trials within the previous 1 month (excluding questionnaire types and specimen collection) 9. currently pregnant, lactating, or planning to be pregnant during the trial 10. have experienced discomfort when wearing silicone hydrogel contact lens, or a known allergy to hyaluronic acid and sodium alginate 11. allergy to any contact lens care product ingredient 12. corrected visual acuity in either eye does not reach 1.0 when wearing the trial lens 13. subjects who are judged by the investigators as unsuitable for the study

Keywords: contact lens
stress management program

Conditions: Stress; Anxiety

Summary: this study will test the immediate and long term (post 4 weeks of daily practice) effectiveness of two breathwork practices, cyclic sighing and box breathing, in comparison to hypnosis and an audiobook about stress, on psychological and physiological variables.


Eligibility criteria:
inclusion criteria: * age 18 or older * no contraindications to mri imaging (like ferromagnetic metal in their body) exclusion criteria: * pregnant or planning to get pregnant during study participation. * not able or willing to come to research location twice for mri assessments

Keywords: stress breathwork cyclic sighing box breathing hypnosis mood anxiety physiology heart rate variability respiratory rate fmri brain activity sleep
postoperative sleep disturbances after zolpidem treatment in fast-track hip and knee replacement

Conditions: Sleep Duration on the First Night After Surgery

Summary: sleep after surgery has been found to be very distrubed immediately after major surgery. this is also seen after fast-track hip and knee replacement with length of stay of less than 3 days. disturbed sleep has many adverse effects i.e. fatigue, possible hyperalgesia and decline in cognitive abilities.


Eligibility criteria:
inclusion criteria: * total hip or knee replacement in fast-track setup * age 60 years or above * asa class 1-3 exclusion criteria: * anesthesia within the pas 30 days * daily use of alcohol \> 21 units / week * use of anxiolytics or hypnotics within the past 30 days * inability to read and understand danish * marked reduction of sight or hearing * parkinson's disease or other neurological disaese causing function deficits * inability to cooperate to sleep monitoring * allergy to the drug tested
safety and efficacy study of adalimumab in patients with active psoriatic arthritis (psa)

Conditions: Psoriatic Arthritis

Summary: the purpose of the study is to assess the safety and clinical efficacy of adalimumab in active psoriatic arthritis (psa) subjects when adalimumab is added to insufficient standard therapy including patients that have failed other tnf therapies


Eligibility criteria:
inclusion criteria: * males and females \> 18 years of age * active psa with \> 3 tender and \> 3 swollen joints despite standard therapy * unsatisfactory response or intolerance to at least one prior or ongoing dmard (study enrollment must be in accordance with current national guidelines for treatment of psa with tnf inhibitors) * a negative serum pregnancy test (serum hcg) for women of childbearing potential prior to the start of treatment. * use of a reliable method of contraception by all female patients of childbearing potential * able and willing to self-administer sc injections or have a suitable person to administer sc injections * able and willing to give written informed consent and comply with the protocol exclusion criteria: * prior treatment with any investigational agent within 30 days or five half lives of the product, whichever is longer * treatment within last 2 months with infliximab or within last 3 weeks with etanercept * treatment within last 4 weeks with a combination of mtx and leflunomide * treatment within last 4 weeks with a combination of cyclosporine with any other dmard-subject has received uva phototherapy (including puva within 2 weeks prior to screening) * history of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin or cervical dysplasia * history of or current active acute inflammatory joint disease of origin other than psa * comorbidities (uncontrolled diabetes, unstable ischemic heart disease, chf, active ibd, stroke within 3 months, chronic leg ulcer and other condition which would put subject at risk by participation in the protocol * positive serology for hepatitis b or c * history of positive hiv status * persistent or recurrent infections or severe infections requiring hospitalization or treatment with iv antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment * females who are pregnant or breast-feeding * history of clinically significant drug or alcohol abuse in the last year * previous diagnosis or signs of central nervous system demyelinating diseases * history of tuberculosis, histoplasmosis or listeriosis * subjects with latent tb or having other risk factors for activation of latent tb who have not initiated a tb prophylaxis prior to the first adalimumab treatment .

Keywords: psoriatic arthritis adalimumab
prognosis and course of covid-19 infection in hospitalised patients

Conditions: Covid19; SARS-CoV Infection

Summary: the aim of the cohort prospective observational study is to define the major factors influencing the course of covid-19 infections and its prognosis in hospitalised patients. the investigators plan to include 300 patients hospitalised with covid-19 infection. the phone contacts with patients are due after 90 and 180 days after discharge.


Eligibility criteria:
inclusion criteria: * hospitalisation with covid-19 exclusion criteria: * history of hospitalisation with covid-19 infection * discharge from the hospital before the end of the treatment course * transfer to another hospital

Keywords: covid-19 chitotriosidase sars-cov infection
phase iii randomized, double-blind study of dexamethasone vs dexamethasone/methylprednisolone vs placebo for bronchopulmonary dysplasia

Conditions: Bronchopulmonary Dysplasia

Summary: objectives: i. compare the efficacy of dexamethasone (dm) vs. dm/methylprednisolone treatment vs. placebo, initiated within the first month of life, on long-term pulmonary and developmental outcomes in premature infants with evolving bronchopulmonary dysplasia. ii. compare the toxicities of these treatments. iii. assess treatment effects on adrenal function.

protocol outline: this is a randomized, double-blind study. patients are randomly assigned to 1 of 3 treatment groups. the first group receives intravenous dexamethasone tapered over 42 days. the second group receives daily intravenous dexamethasone for 6 days, then intravenous methylprednisolone (meprdl) tapered over the next 34 days, beginning on day 8. a placebo is given on "off" meprdl days. the third group receives an intravenous placebo for 42 days, with a tapering schedule beginning day 35. all patients may receive 6 days of dexamethasone rescue therapy beginning day 15 and/or 30, as clinically indicated. study drugs are suspended during rescue therapy.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- premature infants with evolving bronchopulmonary dysplasia on chest x-ray requirement for mechanical ventilation fraction of inspired oxygen greater than 0.30 ventilator at least 15 cycles/minute no signs of weaning within 72 hours prior to entry no serious congenital anomaly --prior/concurrent therapy-- no prior postnatal corticosteroids --patient characteristics-- cardiovascular: no congenital heart disease other: birth weight no greater than 1500 g gestational age no greater than 30 weeks no contraindication to corticosteroids, e.g., culture-proven bacterial sepsis

Keywords: bronchopulmonary dysplasia cardiovascular and respiratory diseases neonatal disorders rare disease
evaluation of de-epithelized connective tissue grafts and modified combined approach for connective tissue grafts

Conditions: Gingival Recession

Summary: this study aims to compare the de-epithelized gingival graft (control group) and modified combined approach for connective tissue graft (test group) in patients undergoing palatal graft harvesting for mucogingival surgery in the oral cavity

harvesting a palatal mucosal tissue graft as an autologous donor for oral soft tissue augmentation is widely practiced. tissue harvest in patients with anatomically thin phenotypes can cause significant morbidity and compromised healing process. the modified combined approach (mca) for connective tissue grafts has the potential for faster healing and fewer postoperative complications, compared to the recommended harvesting technique of de-epithelized gingival graft (dgg). however, the modified combined approach for connective tissue grafts have yet to be extensively investigated. this examiner-masked, randomized study aims to compare post-operative morbidity and treatment outcomes in patients undergoing modified combined approach for connective tissue graft (test group) compared to the de-epithelized gingival graft (control group) harvesting techniques in tissue augmentation. participants will be randomized into two groups receiving one of either modified combined approach for connective tissue graft or de-epithelized gingival graft. collection of the study parameters will utilize both examiner-assessed, and patient reported outcomes. the study will report on the optimum palatal mucosal graft harvesting technique in an asian population. the findings of this study will be utilized to formulate clinical recommendations for soft tissues augmentation in this population.

Eligibility criteria:
inclusion criteria * systemically healthy subjects; * able to give informed consent; * age ≥ 18 years; * requiring palatal tissue harvesting for soft tissue augmentation in the oral cavity exclusion criteria: * subjects with periodontal diseases; * subjects with poor oral hygiene of \>30% plaque index; * pregnant or lactating females; * subjects taking medication with any known effect on the periodontal soft tissues; * subjects with pathology in the oral cavity causing any degree of pain; * subjects wearing removable or fixed prothesis that is in contact with the donor site an * those with allergies to painkillers including ibuprofen and paracetamol.
a safety and efficacy study of pdfe-2304 topical solution for the treatment of androgenic alopecia.

Conditions: Alopecia, Androgenetic; Baldness; Androgenetic Alopecia (AGA)

Summary: this study will evaluate the safety and efficacy of pdfe-2304 compared with minoxidil 5% in men with androgenic alopecia (aga).


Eligibility criteria:
inclusion criteria - * men who have a presentation of androgenetic alopecia (norwood ii - v). * age between 18 to 60 years of age (both inclusive). * have no abnormal findings during physical examination. * able to comply with the study procedures in the opinion of the pi/ci. * able to give written consent for participation in the study. exclusion criteria - * known hypersensitivity or idiosyncratic reaction to the api´s. * clinical diagnosis of non-aga forms of alopecia. * history of hair transplants. * subject having dyed or bleached hair 12 months prior to study start. * use of any topical product in the target region in the last 6 months. * a medical history of receiving chemotherapy/cytotoxic agents. * uncontrolled hypertension. * any dermatological disorders (eczema, psoriasis, sun damage, skin cancer). * hormonal diseases such as thyroid disorders or diabetes. * liver and kidney disease. * smokers. * drug or alcohol abuse within 12 months. * no written consent. * the receipt of an investigational product or participation in a drug research study within a period of 90 days prior to the first dose of study drug.

Keywords: double blind randomized efficacy tolerability comparison treatment